Quarterly Report
Quarterly Report
Sydney, Jan 30, 2019 AEST (ABN Newswire) - Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

The financial highlights for the quarterly reporting period include:

- Cash as at 31 December 2018 of $1.1 million (30 September $2.7 million)

- Net operating cash outflow for the quarter of $1.6 million, consistent with prior quarters

The Company's cash position was $1.1 million as at 31 December. The sources of funding for the Company over the next 18 months include: loan arrangements such as extension to current loan facilities; milestone payments and anticipated clinical licensing opportunities for Progenza; shareholder loan repayments relating to the funding of employee options exercised as part of the IPO in 2013; ongoing R&D Tax Incentives including forward funding arrangements where necessary; capital raisings and existing options exercised. These sources of cash are expected to provide sufficient funding to support the Company's R&D, clinical trials and operating activities for FY'19 and into FY'20.

To view the release, please visit:

About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.



Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au

Daniel Paperny
Media and Capital Partners
T: +61-405-191-257
E: Daniel.paperny@mcpartners.com.au

Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 41) (Last 30 Days: 84) (Since Published: 3162)